Target effector role of vascular endothelium in the inflammatory response: Insights from the clinical trial of anti-TNFα antibody in rheumatoid arthritis

Journal of Clinical Pathology - Molecular Pathology

Volumn 50, Issue 5, 1997, Pages 225-233

  Paleolog, Ewa ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Endothelium; Rheumatoid arthritis; Tumour necrosis factor

Indexed keywords

CELL ADHESION MOLECULE; CHEMOATTRACTANT; CYTOKINE; MONOCLONAL ANTIBODY CA2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; INFLAMMATION; INFLAMMATORY CELL; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; VASCULAR ENDOTHELIUM;

EID: 0030680171     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.50.5.225     Document Type: Review

References (91)

1. Colville-Nash PR, Scott DL. Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis 1992;51:919-25.
2. Sewell KL, Trentham DE. Pathogenesis of rheumatoid arthritis. Lancet 1993;341:283-6.
3. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1995;14:397-440.
4. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10.
5. Ziff M. Role of the endothelium in chronic inflammatory synovitis. Arthritis Rheum 1991;34:1345-52.
6. Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1α. Clin Exp Immunol 1988;73:449-55.
7. Chu CQ, Field M, Abney E, Zheng RQ, Allard S, Feldmann M, et al. Transforming growth factor-β1 in rheumatoid synovial membrane and cartilage-pannus junction. Clin Exp Immunol 1991;86:380-6.
8. Sano H, Forough R, Maier JA, Case JP, Jackson A, Engleka K, et al. Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints. J Cell Biol 1990;110:1417-26.
9. Remmers EF, Sano H, Wilder RL. Platelet-derived growth factors and heparin-binding (fibroblast) growth factors in the synovial tissue pathology of rheumatoid arthritis. Semin Arthritis Rheum 1991;21:191-9.
10. Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK, et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992;90:772-9.
11. Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, Burdick MD, et al. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest 1994;94:1012-18.
12. Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, Burdick MD, et al. Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. J Clin Invest 1994;93:921-8.
13. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994;152:4149-56.
14. Koch AE, Kunkel SL, Shah MR, Hosaka S, Halloran MM, Haines GK, et al. Growth-related gene product α. A chemotactic cytokine for neutrophils in rheumatoid arthritis. J Immunol 1995;155:3660-6.
15. Lafyatis R, Thomson NL, Remmers ER, Flanders KC, Roche NS, Kim SJ. Transforming growth factor-β production by synovial tissues from rheumatoid arthritis patients and streptococcal cell wall arthritis rats. Studies on secretion by synovial fibroblast-like cells and immunohistological localisation. J Immunol 1989;143:1142-8.
16. Brennan FM, Zachariae CO, Chantry D, Larsen CG, Turner M, Maini RN, et al. Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur J Immunol 1990;20: 2141-4.
17. Haworth C, Brennan FM, Chantry D, Turner M, Foxwell B, Maini RN, et al. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumour necrosis factor-α. Eur J Immunol 1991;21: 2575-9.
18. Katsikis P, Chu CQ, Brennan FM, Maini RN, Feldmann M. Immunoregulatory role of interleukin 10 (IL-10) in rheumatoid arthritis. J Exp Med 1994;179:1517-27.
19. Withdrawn.
20. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;ii:244-7.
21. Butler DM, Maim RN, Feldmann M, Brennan FM. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures with an anti-TNFα monoclonal; comparison with blockade of IL-1 using the recombinant IL-1 receptor antagonist. European Cytokine Network 1995;6:225-30.
22. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Nat Acad Sci USA 1992;89:9784-8.
23. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBOJ 1991;10:4025-31.
24. Butler DM, Malfait AM, Mason LJ, Warden PJ, Kollias G, Maini RN, et al. DBA/1 mice expressing the human TNFα transgene develop a severe, erosive arthritis: characterisation of the cytokine cascade and cellular composition. J Immunol 1997;159:2867-76.
25. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNFα. Arthritis Rheum 1993;36:1681-90.
26. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smollen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344:1105-10.
27. Withdrawn.
28. Cronstein BN. Adhesion molecules in the pathogenesis of rheumatoid arthritis. Curr Opin Rheumatol 1994;6:300-4.
29. Issekutz AC, Meager A, Otterness I, Issekutz TB. The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leucocyte and T lymphocyte recruitment to joint inflammation in adjucant arthritis. Clin Exp Immunol 1994; 97:26-32.
30. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994;84:2068-101.
31. Kansas GS. Selectins and their ligands: current concepts and controversies. Blood 1996;88:3259-87.
32. Luscinskas FW, Gimbrone MA. Endothelial-dependent mechanisms in chronic inflammatory leukocyte recruitment. Annu Rev Med 1996;47:413-21.
33. Pober JS, Gimbrone M Jr, Lapierre IA, Mendrick DL, Fiers W, Rothlein R, et al. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol 1986;137:1893-6.
34. Carlos TM, Schwartz BR, Kovach NL, Yee E, Rosso M, Osborn L, et al. Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood 1990;76:965-70.
35. Paleolog EM, Aluri GA, Feldmann M. Contrasting effects of interferon γ and interleukin 4 on responses of human vascular endothelial cells to tumour necrosis factor α. Cytokine 1992;4:470-8.
36. Saklatvala J, Davis W, Guesdon F. Interleukin 1 (IL1) and tumour necrosis factor (TNF) signal transduction. Phil Trans R Soc London R 1946;351:151-7.
37. Majewska E, Paleolog E, Baj Z, Kralisz U, Feldmann M, Tchorzewski H. Role of tyrosine kinase enzymes in TNF-α and IL-1 induced expression of ICAM-1 and VCAM-1 in human umbilical vein endothelial cells. Scand J Immunol 1997;45:385-92.
38. Slowik MR, De Luca LG, Fiers W, Pober JS. Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration. Am J Pathol 1993;143:1724-30.
39. Paleolog EM, Delasalle SAJ, Buurman WA, Feldmann M. Functional activities of receptors for tumour necrosis factor-α (TNF-α) on human vascular endothelial cells. Blood 1994;84:2578-90.
40. Chu CQ, Held M, Feldmann M, Maini RN. Localization of tumor necrosis factor α in synovial tissue and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125-32.
41. Deleuran BW, Chu CQ, Held M, Brennan FM, Mitchell T, Feldmann M, et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum 1992;35:1170-8.
42. Koch AE, Burrows JC, Haines GK, Carlos TM, Harlan JM, Leibovich SJ. Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues. Lab Invest 1991;64:313-20.
43. Johnson BA, Haines GK, Harlow IA, Koch AE. Adhesion molecule expression in human synovial tissue. Arthritis Rheum 1993;36:137-46.
44. El-Gabalawy H, Gallatin M, Vazeux R, Peterman G, Wilkins J. Expression of ICAM-R (ICAM-3), a novel counter-receptor for LFA-1, in rheumatoid and nonrheumatoid synovium. Arthritis Rheum 1994;37:846-54.
45. Szekanecz Z, Haines GK, Lin TR, Harlow IA, Goerdt S, Rayan G, et al. Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and diseased human synovia. Their possible pathogenetic and clinical significance in rheumatoid arthritis. Arthritis Rheum 1994;37:221-31.
46. Maini RN, Elliott MJ, Brennan FM, Williams RO, Chu CQ, Paleolog E, et al. Monoclonal anti-TNFα antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunologkai Reviews 1995;144:195-223.
47. Tak PP, Taylor PC, Breedveld FC, Smeets TJM, Daha MR, Kluin PM, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor a monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1077-81.
48. Gearing AJH, Newman W. Circulating adhesion molecules in disease. Immunology Today 1993;14:506-12.
49. Lobb RR, Chi-Rosso G, Leone DR, Rosa MD, Bixler S, Newman BM, et al. Expression and functional characterization of a soluble form of endothelial-leukocyte adhesion molecule-1. J Immunol 1991;147:124-9.
50. Lobb R, Chi-Rosso G, Leone D, Rosa M, Newman B, Luhowskyj S, et al. Expression and functional characterization of a soluble form of vascular cell adhesion molecule-1. Biochem Biophys Res Commun 1991;178:1498-504.
51. Cush JJ, Rothlein R, Lindsley HB, Mainolfi EA, Lipsky PE. Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum 1993;36:1098-102.
52. Wellicome SM, Kapahi P, Mason JC, Lebranchu Y, Yarwood H, Haskard DO. Detection of a circulating form of vascular cell adhesion molecule-1 : raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 1993;92:412-18.
53. Blann AD, McCollum CN, Steiner M, Jayson MIV. Circulating adhesion molecules in inflammatory and atherosclerotic vascular disease. Immunol Today 1995;16: 251-2.
54. Aoki S, Imai K, Yachi A. Soluble intercellular adhesion molecule-1 (ICAM-1) antigen in patients with rheumatoid arthritis. Scand J Immunol 1993;38:485-90.
55. Mason JC, Kapahi P, Haskard DO. Detection of increased levels of circulating intercellular adhesion molecule 1 in some patients with rheumatoid arthritis but not in patients with systemic lupus erythematosus. Lack of correlation with levels of circulating vascular cell adhesion molecule 1. Arthritis Rheum 1993;36:519-27.
56. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN. Deactivation of vascular endothelium by monoclonal anti-rumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum 1996;39:1082-91.
57. Leeuwenberg JF, Smeets EF, Neefjes JJ, Shaffer MA, Cinek T, Jeunhomme TM, et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 1992;77:543-9.
58. Pigott R, Dillon LP, Hemingway IH, Gearing AJ. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992;187:584-9.
59. Withdrawn.
60. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS 1997;79:1-8.
61. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995,1:27-31.
62. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
63. Peacock DJ, Banquerigo ML, Brahn F. Angiogenesis inhibition suppresses collagen arthritis. J Exp Med 1992;175: 1135-8.
64. Oliver SJ, Banquerigo ML, Brahn F. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell Immunol 1994;157:291-9.
65. Oliver SJ, Cheng TP, Banquerigo ML, Brahn F. Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cell Immunol 1995;166:196-206.
66. Dvorak HF, Detmar M, Claffey KP, Nagy JA, Van de Water L, et al. Vascular permeability factor vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Im Arch Allergy Immunol 1995;107:233-5.
67. Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev 1996;15;165-76.
68. Paleolog E. Angiogenesis: a critical process in the pathogenesis of RA - a role for VEGF? Br J Rheumatol 1996;35:917-20.
69. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 1996;271:603-6.
70. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, et al. Vascular permeability factor, endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994;180:341-6.
71. Nagashima M, Yoshino S, Ishiwata T, Asano G. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol 1995;22:1624-30.
72. Tanaka Y, Adams DH, Shaw S. Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes. Immunol Today 1993;14:111-15.
73. Kakimoto K, Nakamura T, Ishii K, Takashi T, Iigou H, Yagita H, et al. The effect of anti-adhesion molecule-antibody on the development of collagen-induced arthritis. Cellular Immunology 1992;142:326-37.
74. Issekutz AO, Issekutz TB. A major portion of polymorphonuclear leukocyte and T lymphocyte migration to arthritic joints in the rat is via LFA-1/Mac-1-independent mechanisms. Clin Immunol Immunopathol 1993;67:257-63.
75. Wahl SM, Allen JB, Hines KL, Imamichi T, Wahl AM, Furcht LT, et al. Synthetic fibronectin peptides suppress arthritis in rats by interrupting leukocyte adhesion and recruitment. J Clin Invest 1994;94:655-62.
76. Jorgensen C, Couret I, Canovas F, Bologna C, Brochier J, Reme T, et al. Mononuclear cell retention in rheumatoid synovial tissue engrafted in severe combined immunodeficient (SCID) mice is up-regulated by tumour necrosis factor-alpha (TNF-alpha) and mediated through intercellular adhesion molecule-1 (ICAM-1). Clin Exp Immunol 1996;106:20-5.
77. Kavanaugh AF, Davis LS, Nichols LA, Norris SH, Rothlein R, Scharschmidt LA, et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994;37: 992-9.
78. Fava RA, Hunt J, Stevenson S, Nagy J, Shuto T, Esposito P, et al. Role for VEGF and flk-1 in endochondral bone formation. Arthritis Rheum 1996;39:S272.
79. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.
80. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994;367:576-9.
81. Aiello LP, Pierce LP, Foley ED, Takagi H, Chen H, Riddle L, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1994;92:10457-61.
82. Cheng SY, Huang HJS, Nagane M, Ji XD, Wang D, Shih CCY, et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1996;93:8502-7.
83. Wrighton CJ, Hofer-Warbinek R, Moll T, Eytner R, Bach FH, De Martin R. Inhibition of endothelial cell activation by adenovirus-mediated expression of IκBα, an inhibitor of the transcription factor NF-κB. J Exp Med 1996;183:1013-22.
84. Blake DR, Merry P, Unsworth J, Kidd BL, Outhwaite JM, Ballard R, et al. Hypoxic-reperfusion injury in the inflamed human joint. Lancet 1989;8633:289-93.
85. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995;270:19761-6.
86. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or chronic hypoxia. J Clin Invest 1995;95:1798-807.
87. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995;55:6161-5.
88. Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94:1320-7.
89. Bischoff J. Cell adhesion and angiogenesis. J Clin Invest 1997;99:373-6.
90. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct aV integrins. Science 1995;270:1500-2.
91. Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995;376: 517-19.